In FLT3-ITD-dependent AML, ONO-7475 can synergize with sorafenib (a multikinase inhibitor) and venetoclax (a BCL-2 inhibitor) to address resistance to FLT3 and BCL-2 inhibitors, respectively.250,251 In addition, combining ONO-7475 with Osimertinib (an EGFR inhibitor) has demonstrated efficacy in suppressing resistance in EGFR-mutated NSCLC cells that overexpress AXL.252. This evidence concerns the gene BCL2 and acute myeloid leukemia.